Over the last 25 years, the pharmaceutical industry has been instrumental in advancing clinical care, drug efficacy, availability and a positive contribution to economic growth. The industry now faces, however, significant uncertainty due to competitive pressures, increased regulatory risks and changes, and unpredictable product pipelines.
The pharmaceutical industry has evolved as a product of itsí ability to manage innovation and costs. Cost pressures and a decline in R&D productivity has however resulted in a structural shift in the industry. Specialist mono-line or generic manufacturers have found themselves better equipped to respond to the lower-margin market opportunities than larger pharmaceutical conglomerates.
Our approach is to support the evolution of the emerging business models through the effective implementation of:
- Information management and analytics
- Financial processes & IP management
- Business re-engineering
- Risk management
- Performance improvement
- Programme management